ライフサイエンスコーパス: neomycin

1 cally (kanamycin and furosemide) or locally (neomycin).

2 in, amoxicillin, or a cocktail of ampicillin/neomycin.

3 uclear translocation, which was inhibited by neomycin.

4 n the same regions highlighted on the PPT by neomycin.

5 ntibacterial activity compared to the parent neomycin.

6 response of hair cells to the aminoglycoside neomycin.

7 toring sensitivity to kanamycin B but not to neomycin.

8 f D193 for catalyzing the phosphorylation of neomycin.

9 and D4945 was confirmed using the polycation neomycin.

10 ally deafened by an intrascalar injection of neomycin.

11 t cells in the presence of the inhibitor and neomycin.

12 endogenous component of saliva), as well as neomycin.

13 NG nuclear translocation with the antibiotic neomycin.

14 poly(dT) much more than its parent compound, neomycin.

15 ghest, almost 1000-fold greater than that of neomycin.

16 H2O-D2O) < 0), while the reverse is true for neomycins.

17 confer resistance against kanamycins but not neomycins.

18 jects received either erythromycin 250 mg or neomycin 1 g orally QID until hospital discharge or pres

19 her analogues, previously synthesized pyrene-neomycin (1) and BQQ-neomycin (2) conjugates, in our inv

20 usly synthesized pyrene-neomycin (1) and BQQ-neomycin (2) conjugates, in our investigations.

21 The polycation neomycin (250-500 microM) reduced the PIP(2)-induced inw

22 re of such interactions, naphthalene diimide-neomycin (3) and anthraquinone-neomycin (4) conjugates w

23 Contrary to neomycin, 3 destabilizes poly(dA).2poly(dT) triplex but

24 alene diimide-neomycin (3) and anthraquinone-neomycin (4) conjugates were synthesized and used togeth

25 nimals treated with higher concentrations of neomycin (50-200 microM) had more severe and heterogeneo

26 ns have comparable antibacterial activity as neomycin, a clinically used aminoglycoside antibiotic, a

27 Here, we demonstrate that neomycin, a drug that masks the cellular substrate of PI

28 derivatives for RRE specificity, a series of neomycin-acridine conjugates with variable linker length

29 Finally, neomycin administration reduced tumor growth of HepG2-LX

30 Spermine, poly-D-lysine, and neomycin all reduced the baseline HCO(3)(-)-induced inwa

31 s, or with the gut-restricted aminoglycoside neomycin alone, accelerated phagocyte turnover and incre

32 Neomycin also changed the composition of the ileal bacte

33 Metagenomic analyses revealed that neomycin altered the abundance of intestinal bacteria be

34 mma) mediated ANG's nuclear translocation by neomycin, an aminoglycoside antibiotic (not G418-neomici

35 e binding to B-DNA structures by conjugating neomycin, an aminoglycoside antibiotic, with the B-DNA m

36 e binding to B-DNA structures by conjugating neomycin, an aminoglycoside antibiotic, with the B-DNA m

37 duced channel reactivation and inhibition by neomycin, an antagonist of PIP2 binding.

38 Neomycin, an antibiotic, blocked the effects of osteopon

39 we show that a single topical application of neomycin, an inexpensive and vaginally nontoxic antibiot

40 cilitate the synthesis of paromomycin and/or neomycin analogues, we describe a cleavage of ring I fro

41 t of approximately 2 x 10(5) M(-)(1) between neomycin and an intramolecular triplex and a higher K(a)

42 First, two PIP(2) sequestering agents, neomycin and anti-PIP(2), applied to the intracellular s

43 and validate 2-split Hygromycin, Puromycin, Neomycin and Blasticidin resistance genes as well as mSc

44 Here it is reported that the AGA neomycin and gentamicin elicit acute, phosphatidylinosit

45 s of RNA-protein interactions, we identified neomycin and H33342 as inhibitors of binding of vigilin

46 tify the 1-, 3-, and 2'-amino groups of both neomycin and kanamycin B as being critical functionaliti

47 he binding of the aminoglycoside antibiotics neomycin and kanamycin B to APH(3')-IIIa (an antibiotic

48 To assess the in vivo antitumor activity of neomycin and neamine (a nontoxic derivative of neomycin)

49 is possibility, conformationally constrained neomycin and paromomycin analogues designed to mimic the

50 analogues of the aminoglycoside antibiotics neomycin and paromomycin is described in which ring I, i

51 yl groups mimicking the bound side chains of neomycin and paromomycin, respectively, show excellent a

52 Neomycin and paromomycin, which only differ by their rin

53 acid but were significantly reduced by oral neomycin and polymyxin B, indicating a pathogenetic role

54 nvolved an electrostatic interaction between neomycin and putative regions of negative charge in both

55 ia supplemented with the ototoxic antibiotic neomycin and selected pharmacological agents that influe

56 ne (enoxacin), aminoglycoside (kanamycin and neomycin), and polykeptide (tetracycline) to explore the

57 Increasing concentrations of calcium, neomycin, and a calcimimetic compound suppress PTHrP sec

58 OXSI-2, the phospholipase C (PLC) inhibitor neomycin, and either the inositol triphosphate (IP(3)) r

59 Ca(2+)(o), neomycin, and gentamicin also activated the extracellula

60 Enoxacin, kanamycin, neomycin, and tetracycline show synergistic growth inhib

61 phospholipase C (PLC) inhibitors U-73122 and neomycin, and was invariably accompanied by a transient

62 We report herein novel neomycin- and Hoechst 33258-based conjugates developed i

63 nce that blockage of PLC-gamma activation by neomycin appears to be mediating the inhibition of laten

64 1 is 3.2 muM with protection against 200 muM neomycin approaching 100%.

65 -7.5) with poly(dA).2poly(dT) as compared to neomycin ( approximately 6.5).

66 ization-based screening was used to identify neomycin as a pre-miR-21 binding ligand.

67 ese observations emphasize the usefulness of neomycin as a probe for regions of charge in both the cy

68 , each hairpin bound multiple equivalents of neomycin at the higher [RNA].

69 ues for paromomycin (0.5 +/- 0.2 microM) and neomycin B (0.6 +/- 0.2 microM).

70 Here, we have used the aminoglycoside neomycin B (NB) to examine which structural features of

71 samine ring of the aminoglycoside antibiotic neomycin B (ring II) was conjugated to a 16-mer peptide

72 A conformationally constrained neomycin B analogue displays a rather high affinity to t

73 aptamers for streptomycin, chloramphenicol, neomycin B and ATP identifies 37 candidate sequences (in

74 ed hexa-guanidinium and -lysyl conjugates of neomycin B and compared their inhibitory potential.

75 Neomycin B and kanamycin B bind to pre-tRNAAsp with a Kd

76 xhibited a significantly higher affinity for neomycin B and tobramycin than for paromomycin (K(d)s =

77 The higher affinity of the E. coli H69 for neomycin B and tobramycin, as compared to paromomycin an

78 entified the small molecules pentamidine and neomycin B as compounds that disrupt MBNL1 binding to CU

79 s, with the RNA binding of paromomycin I and neomycin B being linked to the protonation of four and a

80 he internal loops selected to bind 5''-azido-neomycin B bind with an affinity similar to that of the

81 amine derivative; and 5'UNNG3' loops for the neomycin B derivative.

82 n potential GA pairs that also recognize the neomycin B derivative.

83 ile synthetic protocol for the production of neomycin B derivatives with various modifications at the

84 icing of 2 pre-mRNAs affected in DM, whereas neomycin B had no effect.

85 e of neomycin B is 500-fold more potent than neomycin B in inhibiting bacterial RNase P, we synthesiz

86 finding that the hexa-arginine derivative of neomycin B is 500-fold more potent than neomycin B in in

87 pH 9.0, the RNA binding of paromomycin I and neomycin B is coupled to the uptake of 3.25 and 3.80 pro

88 icroM RNA, the A-site hairpin bound a single neomycin b molecule.

89 Methanolysis of neomycin B under acidic conditions produced the bicyclic

90 ves of kanamycin A, tobramycin, neamine, and neomycin B via two-dimensional combinatorial screening,

91 lowest pK(a), with this value being 6.92 in neomycin B, 7.07 in paromomycin I, and 7.24 in lividomyc

92 The specificity of neomycin B, a highly potent AMG antibiotic, to the ribos

93 d ternary complexes of APH with kanamycin A, neomycin B, and metal-nucleotide.

94 is, and evaluation of derivatives based upon neomycin B, kanamycin A, and tobramycin conjugates of 9-

95 A internal loops that bind to derivatives of neomycin B, neamine, tobramycin, and kanamycin A.

96 mine the pK(a) values of the amino groups in neomycin B, paromomycin I, and lividomycin A sulfate, wi

97 mycin A, kanamycin B, tobramycin, sisomicin, neomycin B, paromomycin, lividomycin A, and ribostamycin

98 -, 3-, 2'-, and 2"'-amino groups, while, for neomycin B, the binding-linked protonation reactions inv

99 Compared to neomycin B, the derivatives based upon tobramycin and ka

100 The aptamer's affinity for cocaine and neomycin-B decreases with the inclusion of physiological

101 ities for cocaine and analogues, but not for neomycin-B, showing a selective effect of 2AP substituti

102 Neomycin-based derivatives consistently have the highest

103 omycin and neamine (a nontoxic derivative of neomycin), BCBL-1 cells were injected intraperitoneally

104 ne 52 of the Tat protein, rather than to the neomycin binding site.

105 odeling studies show a marked preference for neomycin binding to the larger W-H groove.

106 er of bound water molecules is observed when neomycin binds the enzyme.

107 ns (4,5)P(2)-binding domain was inhibited by neomycin, bisindolylmaleimide I, and anti-type II PtdIns

108 Neomycin block is apparent at both cytosolic and luminal

109 d these data as supporting the proposal that neomycin block of RyR2 involves electrostatic interactio

110 In contrast, neomycin bound preferentially and selectively to the PPT

111 93 residue partially restores sensitivity to neomycin but not to kanamycin B, with the origins of thi

112 t that exposure to amoxicillin or ampicillin/neomycin can alter the biodisposition of acetaminophen a

113 Inhibition by neomycin can be overcome with excess Tdp1 and is greates

114 Although neomycin cannot inhibit miR-21 maturation, linking it to

115 ng a C-to-Y mutation at residue 1532 and the neomycin cassette (C1532Yneo) and those harboring the mu

116 2 mice that were allowed to keep an inverted neomycin cassette (TS2-neo) survived through adulthood.

117 n aberrant Mdm2 allele with insertion of the neomycin cassette and deletion of 184-bp sequence in int

118 1 null mutant mice with a beta-galactosidase-neomycin cassette gene-trap reporter driven from the STO

119 of Pkd1 (Pkd1(cond)) that has an FRT-flanked neomycin cassette inserted into intron 1 and lox P sites

120 Although CD39 mRNA 3' of the neomycin cassette insertion site was detected, brains fr

121 nstrate that the insertion of a loxP-flanked neomycin cassette into RNA polymerase III promoter, whic

122 allele of Smad8 (Smad8(3loxP)) containing a neomycin cassette within intron 3, phenocopy an embryoni

123 the Gbe1 gene and a phosphoglycerate kinase-Neomycin cassette within intron 7, leading to a reduced

124 e first containing a missense mutation and a neomycin cassette, FKRP-Neo(Tyr307Asn) and the second co

125 encode Dvl-binding sequences with IRES-lacZ/neomycin cassettes.

126 re to a high concentration of paromomycin or neomycin caused a variable but significant average incre

127 Surprisingly, however, preorganizing these neomycin-class antibiotics into a TAR-disfavored structu

128 The Kb for the enzyme-neomycin complex showed a complicated dependence on pH,

129 DeltaCp for the APH-neomycin complex was -1.6 kcal x mol(-1) x deg(-1).

130 tonation upon formation of the binary enzyme-neomycin complex.

131 2 degrees C) in the presence of intercalator-neomycin conjugates (1-4) even at a very low concentrati

132 The binding preference of intercalator-neomycin conjugates (1-4) to poly(dA).2poly(dT) was also

133 ies on the interactions between intercalator-neomycin conjugates and a DNA polynucleotide triplex [po

134 st that the binding affinity of intercalator-neomycin conjugates for poly(dA).2poly(dT) increases as

135 ermodynamic parameters of these intercalator-neomycin conjugates with poly(dA).2poly(dT) were derived

136 In contrast to intercalator-neomycin conjugates, the increment of T(m3-->2) of poly(

137 EK-293 cells by colony assay selection for a neomycin-containing transposon.

138 Our data also indicate that neomycin creates greater solvent protection and overall

139 ration that occurs between 12 and 21 h after neomycin damage.

140 blocking antibodies or angiogenin inhibitor neomycin decreased in vitro HSC activation by conditione

141 NA movement is increased by streptomycin and neomycin, decreased by tetracycline, and not affected by

142 clude: loops with potential GA pairs for the neomycin derivative, loops with potential GG pairs for t

143 Surprisingly, when testing synthetic neomycin derivatives against other human pathogens, two

144 Neomycin did not prevent intestinal inflammation or indu

145 In addition, neomycin did not prevent the ability of a structurally u

146 r concentrations of the cationic antibiotic, neomycin, disrupt this protein-lipid interaction and rel

147 exposed to a low, 25-microM concentration of neomycin exhibited hair cells with swollen mitochondria,

148 ed to compare TMP risk between quinolone and neomycin-exposed patients.

149 ls of the adult mouse utricle in response to neomycin exposure in vitro.

150 oral pattern of proliferation in response to neomycin exposure.

151 ration among hair cells within 15 minutes of neomycin exposure.

152 Other neomycin-family aminoglycosides are less potent binders

153 Exposure of 5-d-old larvae to 400 microM neomycin for 1 h results in death of almost all lateral

154 rue null, whereas presence or absence of the neomycin gene has no functional effects.

155 ylation signal, and the SV40 promoter-driven neomycin gene, at a site flanked by the transposon IR el

156 ide and transcriptional start site, with the neomycin gene.

157 ave higher k(cat) values than members of the neomycin group.

158 osides for the host RNA follow the hierarchy neomycin > paromomycin > ribostamycin.

159 ecognition of the novel conjugate containing neomycin, Hoechst 33258, and pyrene.

160 Described herein are novel neomycin-Hoechst 33258 conjugates developed for explorin

161 ttributable mostly to the amino functions of neomycin; however, at neutral pH, functional groups of t

162 These results indicate that the effects of neomycin in adipocytes are not mediated via its ability

163 derivative of the aminoglycoside antibiotic neomycin, in which all of the ammonium groups have been

164 Neomycin induced a redistribution of gut T cells and an

165 excess regenerated hair cells by 48 h after neomycin-induced death but has no effect without previou

166 tion have no effect on the amplitudes of the neomycin-induced substates.

167 angiogenin by the aminoglycoside antibiotic neomycin inhibited PC-3 cell tumor growth in athymic mic

168 In the present study, we report that neomycin inhibits Tdp1 more effectively than the related

169 to Nf1 conditional knockout mice harboring a neomycin insertion (neo) as the germline Nf1 gene mutati

170 Neomycin is a large, positively charged, aminoglycoside

171 Inhibition of Tdp1 by neomycin is observed both with single- and double-strand

172 (2) Triplex stabilization by neomycin is pH dependent (increased pH decreases neomyci

173 (1) Triplex stabilization by neomycin is salt dependent (increased KCl and MgCl(2) co

174 (8) The novel selectivity of neomycin is suggested to be a function of its charge and

175 Neomycin is the most effective aminoglycoside (groove bi

176 der normal growth conditions, the antibiotic neomycin is used to perturb wild-type Escherichia coli.

177 .2poly(dT) increased in the following order: neomycin < 1 < 3 < 4 < 2.

178 tamycin, sisomycin, amikacin, spectinomycin, neomycin), macrolides-lincosamids (erythromycin, lincomy

179 ancomycin, polymyxin B, and Abx (ampicillin, neomycin, metronidazole, and vancomycin).

180 or group B streptococcus, with culture using neomycin-nalidixic acid agar (NNA) and LIM broth.

181 vival in vivo, and targeting ANG function by neomycin/neamine to induce the apoptosis of cells latent

182 green fluorescent protein (EGFP) gene and a neomycin (neo) resistance cassette.

183 The floxed neomycin (Neo)-cassette retained at the targeted H77C al

184 A dimeric neomycin-neomycin conjugate 3 with a flexible linker, 2,

185 Masking PI(4,5)P(2) with neomycin or disrupting PI(4,5)P(2) domains in the plasma

186 We marked several SVAs with either neomycin or EGFP retrotransposition indicator cassettes.

187 animals and were significantly diminished by neomycin or neamine treatments.

188 icant extended survival of mice treated with neomycin or neamine.

189 to lock the hydroxymethyl side chain of the neomycin or paromomycin ring I, as part of the dioxabicy

190 PIP2-channel interaction was inhibited with neomycin or poly-L-lysine.

191 ing PIP(2) antibodies, screening PIP(2) with neomycin, or mutating PIP(2) binding sites (e.g. K188Q),

192 ochaperone NPS R-568, the allosteric agonist neomycin, or the orthosteric agonist Ca(2+) (0.5 or 5 mm

193 e in cleaved caspase-3 were also observed in neomycin- or neamine-treated animal ascitic cells.

194 stituted 2-deoxystreptamine aminoglycosides, neomycin, paromomycin, and ribostamycin, to two differen

195 w that aminoglycosides chemically related to neomycin-paromomycin, ribostamycin and neamine-each bind

196 ion inhibitors, significantly sensitized PC3-neomycin (PC3-neo) cells to TRAIL-induced apoptosis.

197 l antibodies that detect the accumulation of neomycin phosphotranseferase II, the neo gene product, o

198 ene trap integration of a beta-galactosidase-neomycin phosphotransferase (betageo) cassette into the

199 The selectable marker gene neomycin phosphotransferase (NEO) flanked by approximate

200 al locations and containing mutations in the neomycin phosphotransferase (neo) gene were corrected by

201 ial stem cells with a plasmid containing the neomycin phosphotransferase (neo) selectable marker resu

202 enes, encoding Renilla luciferase (Rluc) and neomycin phosphotransferase (Neo), were engineered into

203 of yopE, when fused to the reporter protein neomycin phosphotransferase (Npt), are sufficient for th

204 em consisted of a positive selection for the neomycin phosphotransferase (nptII) gene positioned with

205 tabolism by expressing a phosphoribulokinase-neomycin phosphotransferase fusion protein to produce a

206 Neo coding sequence and expressed functional neomycin phosphotransferase fusion proteins.

207 ring selection with replicons expressing the neomycin phosphotransferase gene (neo replicons).

208 codons 1-10 that, when fused in frame to the neomycin phosphotransferase gene, is sufficient to promo

209 o detect engraftment of cells expressing the neomycin phosphotransferase marker gene suggested the po

210 C-terminal fusions of YscM1 and YscM2 to the neomycin phosphotransferase reporter revealed sequences

211 able markers of bacterial origin such as the neomycin phosphotransferase type II gene, which can conf

212 d yopE gene fusion experiments with the npt (neomycin phosphotransferase) reporter suggest that yscM1

213 sduction) system could deliver enzymes (Cre, neomycin phosphotransferase), transcription factors (NAN

214 he rate of perforation between quinolone and neomycin plus hydrocortisone ear drop-exposed children.

215 ed with increased risk for TMP compared with neomycin plus hydrocortisone, with an adjusted hazard ra

216 isone, ciprofloxacin plus dexamethasone, and neomycin plus hydrocortisone.

217 one, or ciprofloxacin plus dexamethasone) or neomycin plus hydrocortisone.

218 Prenatal neomycin, polymyxin B, and streptomycin treatment protec

219 e, using a combination of three antibiotics--neomycin, polymyxin B, and streptomycin--on diabetes dev

220 as 7 days for povidone-iodine and 7 days for neomycin-polymyxin B-gramicidin (95% confidence interval

221 eatment with povidone-iodine or antibiotics (neomycin-polymyxin B-gramicidin in the Philippines; cipr

222 eported, treatment of 3T3-L1 adipocytes with neomycin prevented the wortmannin inhibition of insulin-

223 In this 420 kb YAC a tauGFP-IRES-Neomycin reporter cassette has been inserted into the PA

224 trap construct contains a beta-galactosidase/neomycin reporter gene, allowing us to stain heterozygot

225 ains a thymidine kinase (tk) gene fused to a neomycin resistance (neo) gene.

226 a cassette encoding sucrose sensitivity and neomycin resistance (sacB-neo) into the small-subunit rR

227 Rs1h-KO) model was created by substituting a neomycin resistance cassette for exon 1 and 1.6 kb of in

228 An insertion of neomycin resistance cassette in intron 10 of Tnnt1 gene

229 a null or severe hypomorph, has an IRES-lacZ-neomycin resistance cassette inserted into the Dlx6 home

230 by replacing exons 4 and 5 in SCN11A with a neomycin resistance cassette, deleting the domain 1 volt

231 Depending on the presence or absence of a neomycin resistance cassette, this genomic rearrangement

232 eplacing parts of intron 4 and exon 5 with a neomycin resistance cassette.

233 ted by replacing ABC-me exons 2 and 3 with a neomycin resistance cassette.

234 mice (MVM) that were designed to introduce a neomycin resistance expression cassette (neo) into the X

235 ited Cre-LoxP technology to generate a novel neomycin resistance gene (neo) cassette-free LTalpha-def

236 We replaced the AP1/NFE2 sites with a neomycin resistance gene (neo) that is flanked by LoxP s

237 isting of a partial 3'-terminal exon [i.e. a neomycin resistance gene (Neo), a poly(A) site, but no 3

238 d a sensitive quantitative PCR assay for the neomycin resistance gene (neoR), and, in a mouse model s

239 ostoc punctiforme were constructed bearing a neomycin resistance gene cassette replacing genes in a p

240 Hepatitis E virus replicons containing the neomycin resistance gene expressed from open reading fra

241 ter containing tetO sequences as well as the neomycin resistance gene under control of the weak H(2)L

242 ovirus immediate early promoter/enhancer and neomycin resistance gene, and was used to transfect IPEC

243 tion of a plasmid coexpressing BC200 and the neomycin resistance gene.

244 a CD20-specific chimeric T-cell receptor and neomycin resistance gene.

245 beled with green fluorescent protein and the neomycin resistance gene.

246 oviral vector (null vector) bearing only the neomycin resistance, neo(r), gene (n = 7), or a retrovir

247 ctors containing a selectable marker such as neomycin resistance.

248 the genes for beta-galactosidase (lacZ) and neomycin resistance.

249 ning a thymidine kinase (tk) gene fused to a neomycin-resistance (neo) gene was stably integrated int

250 d by stringent selection for activation of a neomycin-resistance gene inserted into the endogenous Oc

251 cting for enhanced expression of an inserted neomycin-resistance gene that resulted from losses of he

252 onsisting of a RNA polymerase II promoter, a neomycin-resistance gene, and 5'-splice site) typically

253 e hamster cell line containing an integrated neomycin-resistance marker.

254 sion of green fluorescent protein and stable neomycin-resistant colonies.

255 Titration of all supernatants by neomycin-resistant colony formation assay was also perfo

256 sis induction by mda-7/IL-24 in parental and neomycin-resistant prostate tumor cells.

257 on systems using reporter proteins such as a neomycin-resistant protein (NV replicon-bearing cells) a

258 Treatment of E. coli with the antibiotic neomycin results in the accumulation of a continuum of a

259 Moreover, neomycin reversed the inhibitory effect of wortmannin bu

260 ycin is pH dependent (increased pH decreases neomycin's effectiveness, at a fixed drug concentration)

261 ased KCl and MgCl(2) concentrations decrease neomycin's effectiveness, at a fixed drug concentration)

262 der more native-like infection conditions, a neomycin-selectable marker was inserted into L1/L2 of th

263 els, presumably because of the presence of a neomycin selection cassette in a nearby intron.

264 Using neomycin selection, apoA-IV-overexpressing (+AIV) and co

265 Neomycin selectively stabilizes the triplex (in the pres

266 various antibiotic treatments, we found that neomycin-sensitive bacteria are associated with the indu

267 (5) Neomycin shows a preference for stabilization of TAT tri

268 (4) Neomycin shows nonintercalative groove binding to the DN

269 were deafened by neonatal administration of neomycin that eliminated auditory receptor cells.

270 ementarity to the triplex W-H groove, making neomycin the first molecule that selectively recognizes

271 e replicon in Huh-7 cells in the presence of neomycin, the replication efficiency of the replicon inc

272 The results show high-affinity binding of neomycin to 27-nucleotide model A-site RNA sequence in t

273 We have studied the binding of neomycin to a 171mer RNA (psi-RNA) from the packaging re

274 and D4945N exhibited an attenuated block by neomycin to a greater extent from the cytosolic than lum

275 15N NMR studies showed that binding of neomycin to APH causes upshifts of approximately 1 pKa u

276 lls emerging from organ explants cultured in neomycin to eliminate nonneoplastic host cells.

277 ate but are instead caused by the ability of neomycin to inactivate wortmannin.

278 To test for this we used neomycin to kill hair cells in utricles cultured from mi

279 replacer medicated with oxytetracycline and neomycin to preweaned calves reduced antimicrobial resis

280 sin II with blebbistatin, and treatment with neomycin to sequester phosphatidylinositol 4,5-bisphosph

281 evels in both the amoxicillin and ampicillin/neomycin treated animals.

282 ous KSHV was detected in the supernatants of neomycin-treated BCBL-1 cells than 12-O-tetradecanoylpho

283 Neomycin treatment and ANG silencing inhibited phospholi

284 s dependent on IFN-gamma, ampicillin but not neomycin treatment correlated with accelerated disease a

285 ced by laser ablation in the inner ear or by neomycin treatment in the lateral line, we observe rapid

286 imary route for hair cell regeneration after neomycin treatment in zebrafish.

287 of new hair cells is observed by 24 h after neomycin treatment with nearly complete replacement by 7

288 all upregulated within the first 24 h after neomycin treatment, during the time of maximum prolifera

289 mitochondrial potential decreased following neomycin treatment.

290 e DA-3/TM or DA-3 cells transfected with the neomycin vector only (DA-3/neo) have the same in vivo gr

291 Finally, neomycin was found to inactivate in vitro the PI 3-kinas

292 Uniformly enriched 15N-neomycin was isolated from cultures of Streptomyces frad

293 f T(m3-->2) of poly(dA).2poly(dT) induced by neomycin was negligible under the same conditions.

294 eplicons' ability to transduce resistance to neomycin, we selected replicons with decreased sensitivi

295 ticationic amines (spermine, spermidine, and neomycin) were found to effectively induce the formation

296 lls exposed to the aminoglycoside antibiotic neomycin, whereas inhibition or depletion of exosomes fr

297 CGP 40336A and the aminoglycoside antibiotic neomycin, which bind to different regions of the RNA.

298 mportant for recognition of kanamycin B than neomycin, with mutation of this residue partially restor

299 However, in the presence of neomycin, wortmannin did not inhibit the insulin-stimula

300 For example, a recent study indicated that neomycin would allow insulin-stimulated Glut4 translocat